HEMDental-Care®

Currently in development, HEMDental-Care® targets periodontitis, that is the primary cause of tooth loss.

Serious periodontal diseases were the eleventh most common diseases in the world in 2016.¹

Periodontitis also has consequences outside the oral cavity. Untreated, it can also have repercussions on the patient’s general state of health; these bacteria can enter the blood stream where they are circulated throughout the body. Periodontitis can therefore be associated with severe chronic systemic diseases, respiratory and cardiovascular diseases, worsening diabetes and even an increased risk of cancer.

Current periodontitis therapy essentially consists of partial mechanical cleaning of infected surfaces, supplemented by antibiotic therapy, the long-term use of which may be problematic (resistance/allergic reactions to antibiotics and potential increase in the risk of colorectal cancer). Therefore, our marine hemoglobin-based technology, coupled to a hyaluronic acid gel, can be beneficial in periodontitis treatment. The device currently under development will be capable of delivering oxygen that will inhibit the growth of anaerobic pathogens and promote tissue healing.

“New dental health application for Hemarina’s M101 molecule published in Scientific Reports research journal” Press release

Presentation of HEMDental-Care^® collaborative project (Click to open the PDF file)

 1. WHO – Oral health – 24 September 2018